UTHR Quote, Financials, Valuation and Earnings

Madrigal Pharmaceuticals has a net margin of 40.94% compared to United Therapeutics's net margin of -57.51%. United Therapeutics's return on equity of 20.21% beat Madrigal Pharmaceuticals's return on equity of -63.91%.

United Therapeutics has a consensus price target of $400.48, signalling upside risk potential of 42.44%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 30.56%. Given that United Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe United Therapeutics is more attractive than Madrigal Pharmaceuticals.

United Therapeutics has a beta of 0.632, which suggesting that the stock is 36.833% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are larger than Madrigal Pharmaceuticals quarterly revenues of $103.3M. United Therapeutics's net income of $301.3M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, United Therapeutics's price-to-earnings ratio is 11.43x while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.74x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 40.94% compared to United Therapeutics's net margin of -117.16%. United Therapeutics's return on equity of 20.21% beat Moderna's return on equity of -29.09%.

United Therapeutics has a consensus price target of $400.48, signalling upside risk potential of 42.44%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 98.66%. Given that Moderna has higher upside potential than United Therapeutics, analysts believe Moderna is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.632, which suggesting that the stock is 36.833% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are smaller than Moderna quarterly revenues of $956M. United Therapeutics's net income of $301.3M is higher than Moderna's net income of -$1.1B. Notably, United Therapeutics's price-to-earnings ratio is 11.43x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.74x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 40.94% compared to United Therapeutics's net margin of 2.31%. United Therapeutics's return on equity of 20.21% beat Pfizer's return on equity of 8.91%.

United Therapeutics has a consensus price target of $400.48, signalling upside risk potential of 42.44%. On the other hand Pfizer has an analysts' consensus of $30.73 which suggests that it could grow by 40.28%. Given that United Therapeutics has higher upside potential than Pfizer, analysts believe United Therapeutics is more attractive than Pfizer.

United Therapeutics has a beta of 0.632, which suggesting that the stock is 36.833% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.71% to investors and pays a quarterly dividend of $0.43 per share. United Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are smaller than Pfizer quarterly revenues of $17.8B. United Therapeutics's net income of $301.3M is lower than Pfizer's net income of $410M. Notably, United Therapeutics's price-to-earnings ratio is 11.43x while Pfizer's PE ratio is 15.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.74x versus 1.96x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 40.94% compared to United Therapeutics's net margin of 31.35%. United Therapeutics's return on equity of 20.21% beat Vertex Pharmaceuticals's return on equity of -3.23%.

United Therapeutics has a consensus price target of $400.48, signalling upside risk potential of 42.44%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.94 which suggests that it could grow by 2.83%. Given that United Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe United Therapeutics is more attractive than Vertex Pharmaceuticals.

United Therapeutics has a beta of 0.632, which suggesting that the stock is 36.833% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. United Therapeutics's net income of $301.3M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, United Therapeutics's price-to-earnings ratio is 11.43x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.74x versus 11.40x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.